Alimera Sciences (NASDAQ:ALIM) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Alimera Sciences (NASDAQ:ALIM) in a report released on Wednesday morning. The firm issued a hold rating on the biopharmaceutical company’s stock.

Other analysts have also recently issued reports about the stock. Alliance Global Partners restated a “neutral” rating on shares of Alimera Sciences in a report on Tuesday, June 25th. Maxim Group reissued a “hold” rating on shares of Alimera Sciences in a research note on Tuesday, June 25th. Finally, HC Wainwright cut Alimera Sciences from a “buy” rating to a “neutral” rating and set a $6.00 price target on the stock. in a research note on Tuesday, June 25th.

Alimera Sciences Stock Performance

ALIM opened at $5.54 on Wednesday. Alimera Sciences has a 1-year low of $2.61 and a 1-year high of $5.65. The company has a debt-to-equity ratio of 1.80, a current ratio of 2.79 and a quick ratio of 2.62. The business has a 50 day moving average price of $5.55 and a two-hundred day moving average price of $4.63. The company has a market capitalization of $290.24 million, a price-to-earnings ratio of -3.53 and a beta of 1.25.

Alimera Sciences (NASDAQ:ALIM) last released its earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.02). Alimera Sciences had a negative return on equity of 33.70% and a negative net margin of 14.74%. The firm had revenue of $27.00 million for the quarter, compared to analyst estimates of $25.76 million. Research analysts predict that Alimera Sciences will post -0.13 EPS for the current fiscal year.

Institutional Trading of Alimera Sciences

Several large investors have recently added to or reduced their stakes in ALIM. Glazer Capital LLC acquired a new stake in Alimera Sciences during the 2nd quarter worth about $3,067,000. Vanguard Group Inc. grew its position in Alimera Sciences by 61.1% during the first quarter. Vanguard Group Inc. now owns 1,045,460 shares of the biopharmaceutical company’s stock valued at $4,077,000 after purchasing an additional 396,506 shares in the last quarter. Ancora Advisors LLC acquired a new position in Alimera Sciences in the 1st quarter valued at approximately $915,000. Deltec Asset Management LLC purchased a new stake in Alimera Sciences in the 2nd quarter worth approximately $690,000. Finally, Gabelli Funds LLC acquired a new stake in shares of Alimera Sciences during the 2nd quarter valued at $600,000. 99.83% of the stock is owned by institutional investors and hedge funds.

Alimera Sciences Company Profile

Alimera Sciences, Inc, a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS).